dawn-bio

Executive Summary

Dawn-bio is a Vienna-based biotechnology company revolutionizing reproductive medicine through a proprietary stem-cell platform that decodes the biological signals embryos need to thrive in nature. Founded in 2018, the company aims to translate these insights into the IVF lab, potentially improving embryo selection and culture conditions. By addressing the inefficiencies in current assisted reproductive technologies, dawn-bio’s approach could increase success rates and reduce the emotional and financial burden on patients. The platform uniquely bridges developmental biology and clinical IVF, positioning the company as a key innovator in the fertility space. Although still in the preclinical stage, dawn-bio has the potential to disrupt a large and growing market. The company's ability to secure funding and move towards clinical validation will be critical. If successful, its technology could become a standard adjunct in IVF clinics worldwide, improving outcomes for millions of couples. The management team's expertise and the scientific novelty of the platform underpin a promising, albeit early-stage, investment thesis.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round70% success
• Q4 2026First Clinical Trial Initiation50% success
• Q2 2026Partnership with Major IVF Clinic Network60% success